Triaptosis-based biomimetic nanoparticle for the treatment of oral squamous cell carcinoma lymph node metastasis
- Design
- Cell / in-vitro
- Drugs
- Semaglutide
- Assessment
- Not yet reviewed by a person · added Nov 8, 2026
This study was added automatically and has not been reviewed. Until it is, the collection publishes no population match, weight-loss explanation, study tier, findings, population or funding details for it: a check of automatically extracted details found too many errors to show them as fact. The abstract below is the source as retrieved.
01Source
The source, as retrieved
Abstract
Lymph node metastasis (LNM) is a major determinant of poor prognosis in oral squamous cell carcinoma (OSCC) and remains difficult to treat due to the immunosuppressive tumor microenvironment and limited response to immune checkpoint blockade. Here, we report a biomimetic nanotherapeutic platform designed to induce triaptosis and enhance antitumor immunity for the treatment of metastatic OSCC. Semaglutide-loaded cerium oxide nanoparticles were engineered and further coated with macrophage membranes to construct Semg@Ce@MM, enabling improved tumor targeting and immune compatibility. The nanoplatform exerts dual therapeutic actions: cerium-mediated pro-oxidative activity triggers VPS34-associated triaptosis characterized by cytoplasmic vacuolization, while semaglutide activates MAPK signaling to enhance tumor cell susceptibility to death. In vitro studies demonstrate potent antitumor activity, including inhibition of tumor cell proliferation and invasion. In a lymph node metastasis model, Semg@Ce@MM significantly suppresses metastatic tumor growth, promotes dendritic cell maturation, increases CD4+ and CD8+ T cell infiltration, and reprograms tumor-associated macrophages toward a pro-inflammatory phenotype. Importantly, Semg@Ce@MM synergizes with anti-PD-L1 therapy to overcome resistance to immune checkpoint blockade while maintaining favorable biosafety. This work establishes a triaptosis-based nanomedicine strategy for the treatment of metastatic OSCC and highlights a promising combinatorial approach that integrates oxidative stress mediated cell death with cancer immunotherapy.